Medicare Enrolled
Dr. Manzurul Sikder, MD
Hematology & Oncology · New Hartford, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sikder from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sikder?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sikder
Dr. Manzurul Sikder is a hematology & oncology specialist in New Hartford, NY, with 19 years of NPI registration. Based on federal Medicare data, Dr. Sikder performed 211,487 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Sikder received a total of $119,291 from 47 pharmaceutical and/or device companies across 460 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sikder is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 2% volume in NY
$119,291 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗211,487
Medicare services
Top 2% in NY for hematology & oncology
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
93,000 | $1 | $2 |
| Pembrolizumab injection (Keytruda) | 28,000 | $43 | $65 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
24,720 | $6 | $22 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
14,550 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 13,680 | $18 | $33 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
12,400 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
5,200 | $6 | $35 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,170 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,950 | $1 | $57 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
2,154 | $10 | $40 |
| Anti-nausea injection (ondansetron/Zofran) | 2,112 | $0 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,977 | $90 | $202 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
1,076 | $1 | $9 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
912 | $78 | $291 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
745 | $128 | $284 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
687 | $22 | $63 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
480 | $96 | $248 |
| Injection, potassium chloride, per 2 meq | 460 | $0 | $0 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
348 | $108 | $400 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
245 | $46 | $114 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
227 | $54 | $125 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
215 | $15 | $38 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
122 | $30 | $40 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
103 | $91 | $170 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
89 | $21 | $58 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
82 | $1 | $2 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
78 | $76 | $82 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
78 | $28 | $88 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
71 | $13 | $40 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
70 | $45 | $125 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
63 | $63 | $160 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
57 | $19 | $44 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
55 | $133 | $329 |
| New patient office visit, complex (60-74 min) | 51 | $160 | $335 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
45 | $1 | $4 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
41 | $55 | $118 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
37 | $10 | $30 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
36 | $116 | $265 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
23 | $72 | $78 |
| Blood smear interpretation with written report A physician examines a blood sample slide under a microscope to analyze blood cells. The doctor provides a written report of their findings. |
22 | $18 | $52 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
21 | $96 | $223 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
18 | $133 | $281 |
| Quadrivalent influenza vaccine, cell-culture derived A flu shot containing four strains of influenza virus, produced using cell culture technology rather than eggs. This formulation is free from preservatives and antibiotics. |
17 | $33 | $55 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
44.8% high complexity
53.6% medium
1.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$119,291
Total received (2018-2024)
Avg $17,042/year across 7 years
Top 7% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
460
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,229
2023
$19,808
2022
$6,391
2021
$18,950
2020
$31,931
2019
$18,114
2018
$20,868
Payments by company (2024)
E.R. Squibb & Sons, L.L.C.
$3,043
AstraZeneca Pharmaceuticals LP
$94
Novartis Pharmaceuticals Corporation
$42
Genentech USA, Inc.
$33
Regeneron Healthcare Solutions, Inc.
$17
Top 3 companies account for 98.5% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$84,999
Janssen Pharmaceuticals, Inc
$25,554
Celgene Corporation
$4,487
Novartis Pharmaceuticals Corporation
$619
AstraZeneca Pharmaceuticals LP
$502
Genentech USA, Inc.
$333
Janssen Biotech, Inc.
$312
PFIZER INC.
$287
Amgen Inc.
$223
Astellas Pharma US Inc
$207
Pharmacyclics LLC, An AbbVie Company
$198
Merck Sharp & Dohme Corporation
$175
Alexion Pharmaceuticals, Inc.
$124
AbbVie, Inc.
$97
Kyowa Kirin, Inc.
$96
Gilead Sciences, Inc.
$82
SANOFI-AVENTIS U.S. LLC
$75
Ipsen Biopharmaceuticals, Inc
$68
Takeda Pharmaceuticals U.S.A., Inc.
$59
Janssen Scientific Affairs, LLC
$54
Karyopharm Therapeutics Inc.
$51
Agios Pharmaceuticals, Inc.
$49
Lilly USA, LLC
$49
EMD Serono, Inc.
$46
EISAI INC.
$40
Taiho Oncology, Inc.
$36
Lexicon Pharmaceuticals, Inc.
$35
Merck Sharp & Dohme LLC
$32
Rigel Pharmaceuticals, Inc.
$31
Apellis Pharmaceuticals, Inc.
$30
Sirtex Medical Inc
$30
Seattle Genetics, Inc.
$30
Verastem, Inc.
$25
Clovis Oncology, Inc.
$24
Shire North American Group Inc
$22
Daiichi Sankyo Inc.
$22
GENZYME CORPORATION
$21
Boehringer Ingelheim Pharmaceuticals, Inc.
$21
Eisai Inc.
$20
Spectrum Pharmaceuticals Inc.
$19
Array BioPharma Inc.
$18
Midatech Pharma US Inc
$18
Regeneron Healthcare Solutions, Inc.
$17
HOSPIRA, INC.
$16
Exelixis Inc.
$16
Teva Pharmaceuticals USA, Inc.
$12
Endo Pharmaceuticals Inc.
$11
Top 3 companies account for 96.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Avastin · BAVENCIO · BENDEKA · BOSULIF · Bavencio · Braftovi · CALQUENCE · CHANTIX · CYRAMZA · Cabometyx · Copiktra · Creon · DARZALEX · ELIQUIS · ELITEK · EMPLICITI · ERLEADA · Empaveli · Enhertu · Erivedge · Erleada · FARESTON · Folotyn · GILOTRIF · Gelclair · Halaven · Herceptin · IBRANCE · IDHIFA · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JADENU · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LIBTAYO · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lupron · Lupron Depot · MEKINIST · MVASI · NASCOBAL · NINLARO · Neulasta · OPDIVO · OPDUALAG · PADCEV · PIQRAY · POTELIGEO · PROMACTA · Padcev · Perjeta · Pomalyst · REBLOZYL · RETACRIT · RETEVMO · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · Tavalisse · ULTOMIRIS · VONVENDI · VOTRIENT · XARELTO · XPOVIO · XTANDI · Xermelo · YERVOY · ZERBAXA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
6
County median income
$68,819
Nearest hospital to ZIP centroid (approximate)
MOHAWK VALLEY PSYCHIATRIC CENTER
8.2 mi
8.2 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sikder is a mixed practice specialist, with above-average Medicare volume (top 2% in NY), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sikder experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Sikder performed 93,000 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Sikder receive payments from pharmaceutical companies?
Yes. Dr. Sikder received a total of $119,291 from 47 companies across 460 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sikder's costs compare to other hematology & oncology specialists in New Hartford?
Dr. Sikder's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sikder) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in New Hartford
Browse hematology & oncology specialists in New Hartford ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology